KeyBanc analyst Paul Knight lowered the firm’s price target on West Pharmaceutical to $315 from $350 and keeps an Overweight rating on the shares. Knight sees multiple indicators providing high visibility for the firm’s FY23 quarters and FY25 annual estimates, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on WST: